(CIDRAP News) The avian influenza virus long established in Southeast Asia has reached Europe's doorstep, with confirmation today that a lethal virus in Turkey is H5N1 and that an H5 strain in Romania is still being subtyped.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.
(CIDRAP News) – An H5N1 influenza vaccine made by Baxter International could become the first cell culture–based H5N1 influenza vaccine to be approved for marketing, following its endorsement by a committee of the European Medicines Agency (EMEA) last week.
Recommendations of the Committee for Medicinal Products for Human Use (CHMP) are usually followed by the EMEA within a few months.
WHO's novel H1N1 flu case count tops 4,500The global number of people infected with the novel H1N1 influenza (swine flu) virus rose to 4,694 from 30 countries, the World Health Organization (WHO) reported today. The count includes 1,626 cases and 48 deaths in Mexico and the 2,532 cases and 3 deaths reported in the United States as of yesterday. Canada has reported 284 cases and one death. [WHO update 25]
(CIDRAP News) An article published by the British Medical Journal says three scientists who helped frame World Health Organization (WHO) guidance on pandemic influenza preparedness had consulted for pharmaceutical companies that stood to profit from the WHO guidance and that the WHO did not disclose the scientists' industry ties.